Anti-GD2 antibodies
AssigneeMemorial Sloan Kettering Cancer Center
InventorsNai-Kong Cheung, Mahiuddin Ahmed, Hong Xu
Life of this patent
Estimating the term…
Abstract
In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.
Claims35
A humanized or chimeric antibody or fragment thereof capable of binding to GD2, wherein the antibody or fragment thereof comprises any of the following:
- (i) a variable heavy chain domain of SEQ ID NO:
- 1 and a variable light chain domain of SEQ ID NO:2;
- (ii) a variable heavy chain domain of SEQ ID NO:3 and a variable light chain domain of SEQ ID NO:2;
- (iii) a variable heavy chain domain of SEQ ID NO:4 and a variable light chain domain of SEQ ID NO:5;
- (iv) a variable heavy chain domain of SEQ ID NO:6 and a variable light chain domain of SEQ ID NO:7;
- (v) a variable heavy chain domain of SEQ ID NO:8 and a variable light chain domain of SEQ ID NO:5;
- (vi) a variable heavy chain domain of SEQ ID NO:9 and a variable light chain domain of SEQ ID NO:
- 10;
- and
- (vii) a variable heavy chain domain of SEQ ID NO:6 and a variable light chain domain of SEQ ID NO:
- 5.
A bispecific antibody having first and second antigen binding sites, one of which comprises antigen binding sequences of a light chain and a heavy chain of a humanized 3F8 antibody.
A bispecific T-cell engaging monoclonal antibody comprising a first binding site comprising scFv from hu3F8 monoclonal antibody, and a second binding site binding to a T-cell.
Dependencies are inferred from the claim text.